Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity

What Was Tested

Researchers studied Tirzepatide in the context of sleep apnea (obstructive) in this randomized controlled trial publication.

The researchers evaluated effects of tirzepatide treatment on sleep disturbance, sleep-related impairment, functioning, health-related quality of life (HRQoL), and OSA symptoms in SURMOUNT-OSA participants.

Who Took Part

The abstract describes 52 participants taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

For participants using PAP (Study 2), PAP was withdrawn prior to assessments of polysomnography and patient-reported outcome measures (PROMs).

Changes in sleep-related impairment, sleep disturbance, excessive daytime sleepiness, functioning, and HRQoL were assessed using analysis of covariance.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

Prespecified PROM endpoints were from baseline to Week 52.

Categorical shifts in OSA symptom severity were described.

What Was Measured

PubMed files the paper under topics including Sleep Apnea, Obstructive, Patient Reported Outcome Measures, Quality of Life, Obesity, Polysomnography and Tirzepatide.

Author keywords: Functional status, Health-related quality of life, Obstructive sleep apnea and Patient-reported outcomes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 52 participants in people with sleep apnea (obstructive).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Sleep medicine), a journal based in Netherlands.

More context: the Tirzepatide compound page, Sleep apnea (obstructive) research.